Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Other Accumulated Expenses (2020 - 2025)

Bioventus' Other Accumulated Expenses history spans 6 years, with the latest figure at $4.2 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 7.48% year-over-year to $4.2 million; the TTM value through Dec 2025 reached $4.2 million, up 7.48%, while the annual FY2025 figure was $4.2 million, 7.48% up from the prior year.
  • Other Accumulated Expenses reached $4.2 million in Q4 2025 per BVS's latest filing, down from $4.4 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $10.2 million in Q2 2021 to a low of $3.0 million in Q4 2021.
  • Average Other Accumulated Expenses over 5 years is $4.4 million, with a median of $4.1 million recorded in 2021.
  • Peak YoY movement for Other Accumulated Expenses: tumbled 61.36% in 2022, then surged 35.38% in 2023.
  • A 5-year view of Other Accumulated Expenses shows it stood at $3.6 million in 2021, then grew by 1.38% to $3.6 million in 2022, then skyrocketed by 33.52% to $4.8 million in 2023, then decreased by 18.67% to $3.9 million in 2024, then grew by 7.48% to $4.2 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Other Accumulated Expenses are $4.2 million (Q4 2025), $4.4 million (Q3 2025), and $4.4 million (Q2 2025).